# US 2018/0024141 A1 · Method for the enrichment of circulating tumor dna

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0024141 A1
- Document ID: US20180024141A1
- Status: Published application
- Kind: A1
- Application number: 15/523,280
- Filed: 2015-10-29
- Published: 2018-01-25
- Earliest claimed: 2014-10-29
- Assignees: Belgian Volition SPRL
- Applicants: Belgian Volition SPRL
- Inventors: Jacob Vincent MICALLEF; Marielle HERZOG; Mark Edward ECCLESTON
- Web page: https://patentgrep.com/patent/US20180024141A1

## CPC

- G01N 33/6875: {Nucleoproteins}
- C12N 15/1003: {Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor}
- G01N 27/622: Ion mobility spectrometry
- G01N 2560/00: Chemical aspects of mass spectrometric analysis of biological material
- G01N 2800/7028: Cancer
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to the use of histone binding agents for detecting, isolating and/or purifying cell free nucleosomes of tumor originor circulating tumor DNA from a biological sample. The invention also relates to methods and kits using said histone binding agents.

## Claims

### Claim 1

(canceled)

### Claim 2

A method for isolating circulating cell free nucleosomes of tumor origin from a biological sample by affinity purification wherein said method comprises the steps of:
(i) contacting the sample with a histone H3.1 and/or H3.2 and/or H3t binding agent;
(ii) isolating bound nucleosomes from the sample; and
(iii) analysing the isolated nucleosomes and/or associated DNA.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the step of analysing the isolated nucleosomes and/or associated DNA comprises an immunoassay method.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the step of analysing the isolated nucleosomes and/or associated DNA comprises a proteomics method.

### Claim 5 (depends on 2)

The method according to claim 2, wherein the step of analysing the isolated nucleosomes and/or associated DNA comprises mass spectrometry.

### Claim 6

A method for isolating purified circulating tumor DNA (ctDNA) from a biological sample, wherein said method comprises the steps of:
(i) isolating circulating cell free nucleosomes containing histone H3.1 and/or H3.2 and/or H3t;
(ii) extracting DNA from the nucleosome sample produced in step (i); and
(iii) analysing the extracted DNA.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the step of analysing the extracted DNA comprises: DNA sequencing, methylated DNA sequencing analysis, PCR, BEAMing, NGS (targeted or whole genome), digital PCR, cold PCR (co-amplification at lower denaturation temperature-PCR), MAP (MIDI-Activated Pyrophosphorolysis), PARE (personalized analysis of rearranged ends) or Mass Spectrometry.

### Claim 8

An immunoassay method for detecting an epigenetic epitope of tumor derived circulating nucleosomes in a biological sample, wherein said method comprises the steps of:
(i) contacting the sample with a histone H3.1 and/or H3.2 and/or H3t binding agent;
(ii) contacting the nucleosomes or sample with a second binding agent which binds to said epitope;
(iii) detecting and/or quantifying the binding of said second binding agent to said epitope; and
(iv) using the presence or degree of such binding as a measure of the presence of the particular epitope of tumor derived nucleosomes in the sample.

### Claim 9

An immunoassay method for detecting an epigenetic epitope of tumor derived circulating nucleosomes in a biological sample wherein said method comprises the steps of:
(i) contacting the sample with a first binding agent which binds to said epitope;
(ii) contacting the nucleosomes or sample with a histone H3.1 and/or H3.2 and/or H3t binding agent;
(iii) detecting and/or quantifying the binding of said histone H3.1 and/or H3.2 and/or H3t binding agent to nucleosomes in the sample; and
(iv) using the presence or degree of such binding as a measure of the presence of the particular epitope of tumor derived nucleosomes in the sample.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the epitope comprises a histone modification.

### Claim 11 (depends on 8)

The method according to claim 8, wherein the epitope comprises a modified nucleotide.

### Claim 12 (depends on 8)

The method according to claim 8, wherein the epitope comprises a histone variant or isoform.

### Claim 13 (depends on 8)

The method according to claim 8, wherein the epitope comprises a nucleosome adduct.

### Claim 14 (depends on 2)

The method according to claim 2, wherein the biological sample comprises a blood, serum or plasma sample.

### Claim 15

A method of diagnosing cancer which comprises the step of detecting circulating cell free nucleosome associated histone variant H3.1 and/or H3.2 and/or H3t in a biological sample obtained from a human or animal subject.

### Claim 16 (depends on 15)

The method according to claim 15, which additionally comprises detecting one or more histone modification, modified nucleotide, histone variant or isoform or nucleosome adduct.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the histone modification comprises H3K27Ac and/or 5-methylcytosine.

### Claim 18

(canceled)

### Claim 19 (depends on 2)

The method according to claim 2, wherein the histone H3.1 and/or H3.2 and/or H3t binding agent comprises a H3.1 binding agent.

### Claim 20 (depends on 9)

The method according to claim 9, wherein the epitope comprises a histone modification.

### Claim 21 (depends on 9)

The method according to claim 9, wherein the epitope comprises a modified nucleotide.

### Claim 22 (depends on 9)

The method according to claim 9, wherein the epitope comprises a histone variant or isoform.

### Claim 23 (depends on 9)

The method according to claim 9, wherein the epitope comprises a nucleosome adduct.

### Claim 24 (depends on 8)

The method according to claim 8, wherein the biological sample comprises a blood, serum or plasma sample.

### Claim 25 (depends on 9)

The method according to claim 9, wherein the biological sample comprises a blood, serum or plasma sample.

### Claim 26 (depends on 8)

The method according to claim 8, wherein the histone H3.1 and/or H3.2 and/or H3t binding agent comprises a H3.1 binding agent.

### Claim 27 (depends on 9)

The method according to claim 9, wherein the histone H3.1 and/or H3.2 and/or H3t binding agent comprises a H3.1 binding agent.
